There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for BioVie Inc (BIVI) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.04, or -0.99%, to $4.01. The BioVie Inc has recorded 2,036 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2023.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $4.05 and fluctuated between $4.4399 as its day high and $3.8765 as its day low. The current market capitalization of BioVie Inc is $152.85M. A total of 0.67 million shares were traded on the day, compared to an average of 396.47K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, BIVI has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 19,365 shares. Over the last 12 months, there were 12 BUYs and 13 SELLs from insiders. Insiders purchased 624,010 shares during that period but sold 58,666.
In the most recent transaction, GORLIN STEVE sold 8,560 shares of BIVI for 3.05 per share on Sep 05. After the transaction, the Director now owns 75,680 company shares. In a previous transaction on Aug 22, BERMAN RICHARD J sold 10,805 shares at 3.50 per share. BIVI shares that Director owns now total 16,789.
Among the insiders who sold shares, BERMAN RICHARD J disposed of 5,984 shares on Jun 07 at a per-share price of $5.81. This resulted in the Director holding 23,210 shares of BIVI after the transaction. In another insider transaction, BERMAN RICHARD J sold 5,000 shares at $6.50 per share on May 22. Company shares held by the Director now total 29,194.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for BIVI in the last 3 months, the mean price target is $12.00 with high estimates of $12.00 and low estimates of $12.00. In terms of 52-week highs and lows, BIVI has a high of $14.38 and a low of $2.31.
As of this writing, BIVI has an earnings estimate of -$0.28 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.32. The company reported an EPS of -$0.25 in the last quarter, which was 37.50% higher than expectations of -$0.4.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BIVI’s latest balance sheet shows that the firm has $18.64M in Cash & Short Term Investments as of fiscal 2022. There were $12.26M in debt and $4.17M in liabilities at the time. Its Book Value Per Share was $0.20, while its Total Shareholder’s Equity was $3.67M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BIVI is Buy with a score of 5.00.